Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sight SciencesSGHT -1.22%72 Debt-to-Equity is 0.78 as of Mar. 2026, which is 200% above its 10-year median of 0.26. GuruFocus rates SGHT with a GF Score™ of 72/100 and a GF Value™ of $4.53 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 705 Medical Devices & Instruments companies, Sight Sciences ranks worse than 79.86% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Sight Sciences's Debt-to-Equity or its related term are showing as below:
SGHT'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.37 Med: 0.26 Max: 0.78
Current: 0.78
During the past 8 years, the highest Debt-to-Equity Ratio of Sight Sciences was 0.78. The lowest was -0.37. And the median was 0.26.
SGHT's Debt-to-Equity is ranked worse than 79.86% of 705
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs SGHT: 0.78
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Sight Sciences Debt-to-Equity Related Terms
Sight Sciences Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Sight Sciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SGHT vs TMCI, TLSI, SENS: Debt-to-Equity Comparison
For the Medical Devices subindustry, Sight Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sight Sciences Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sight Sciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Sight Sciences's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sight Sciences (SGHT) has a Debt-to-Equity of 0.78 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sight Sciences and its competitors. This is 200% above median its historical median of 0.26. According to the industry distribution chart, Sight Sciences ranks #563 out of 705 companies in the Medical Devices & Instruments industry, placing it in the top 79.9%.
Is Sight Sciences' Debt-to-Equity too high?
Sight Sciences' current Debt-to-Equity of 0.78 is 200% above median its 10-year median of 0.26. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Sight Sciences' value of 0.78 is 239.1% above this industry median. Based on the distribution chart, Sight Sciences ranks #563 out of 705 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sight Sciences has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sight Sciences' Debt-to-Equity compare to TMCI and TLSI?
According to the Medical Devices & Instruments industry distribution chart, Sight Sciences ranks #563 out of 705 companies for Debt-to-Equity. This places Sight Sciences in the lower half of its industry. The industry median Debt-to-Equity is 0.23. Sight Sciences' value of 0.78 is 239.1% above this benchmark. While the company's 10-year median is 0.26 vs. the industry median of 0.23, Sight Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sight Sciences's current Debt-to-Equity of 0.78 is 239.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sight Sciences and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sight Sciences's current Debt-to-Equity is 0.78, which is 200% above median its own 10-year median of 0.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sight Sciences stock overvalued right now?
Based on GuruFocus' analysis, Sight Sciences (SGHT) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.53, compared to a current price of $5.27 — trading 16.3% above its estimated fair value. The current Debt-to-Equity is 0.78, which is 200% above median its 10-year median of 0.26 and 239.1% above the Medical Devices & Instruments industry median of 0.23. Sight Sciences' overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Sight Sciences (SGHT), the current Debt-to-Equity is 0.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sight Sciences (SGHT) Overvalued in 2026?
Based on GuruFocus' analysis, Sight Sciences stock appears to be overvalued.
The current stock price of $5.27 is trading 16.3% above its estimated GF Value™ of $4.53.
GuruFocus considers Sight Sciences to be Modestly Overvalued.
Key valuation signals for SGHT:
Debt-to-Equity: 0.78 (200% above median its 10-year median of 0.26)
GF Value™: $4.53 vs. price of $5.27 (16.3% above fair value)
Industry Position: 239.1% above the Medical Devices & Instruments median (#563 of 705)
No single metric tells the full story. See the SGHT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
72GF Score
Get the complete analysis for SGHT
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGHT has been successfully added to your 
